Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
29 hedge funds and large institutions have $5.14M invested in Bellicum Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 11 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
11% less capital invested
Capital invested by funds: $5.76M → $5.14M (-$612K)
15% less funds holding
Funds holding: 34 → 29 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$142K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$118K |
| 4 |
LPL Financial
San Diego,
California
|
+$72.6K |
| 5 |
Bank of New York Mellon
New York
|
+$57.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$563K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$350K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$235K |
| 4 |
Renaissance Technologies
New York
|
-$94K |
| 5 |
Millennium Management
New York
|
-$57K |
BLCM Hedge Fund Activity: Q1 2021 in Review
29 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2021, worth a combined $5.14M — down 11% from $5.76M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BLCM and 6 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $142K. The largest seller was Sabby Management, exiting entirely with an estimated $563K sold.
- 29 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2021, down from 34 in Q4 2020.
- Funds reported $5.14M of Bellicum Pharmaceuticals, Inc. stock for Q1 2021, down 11% quarter-over-quarter.
- 6 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2021 and 11 closed out, a net change of -5 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2021 was Acadian Asset Management, an estimated $142K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2021 was Sabby Management, an estimated $563K sold.
Based on aggregated 13F filings for Q1 2021.